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Background: ErbB4 expression has been noted in various tumors, but its regulatory mechanism in esophageal
squamous cell carcinoma (ESCC) remains unclear. The aim of this study was to investigate whether miR-302b
regulates the expression of ErbB4 at the post-transcriptional level and to determine its expression, significance,
and function in ESCC.
Methods: We used real-time reverse transcriptase-polymerase chain reaction to quantify the expression of miR-302b
in 50 ESCC tissues and analyzed its relationship with clinicopathological factors and survival. Then, we investigated the
post-transcriptional regulation of ErbB4 expression using immunoblot analysis and luciferase reporter assays. Finally,
the effects of miR-302b on proliferation, apoptosis, and invasion of ESCC cells was detected using MTT, flow cytometric
analysis, and transwell invasion assays, respectively.
Results: miR-302b was significantly down-regulated and correlated with tumor differentiation and lymph node
metastasis in ESCC. Univariate and multivariate analyses indicated that low miR-302b expression might be a poor
prognostic factor. Further studies demonstrated that miR-302b post-transcriptionally down-regulated the expression
of ErbB4 in vitro. Moreover, miR-302b inhibited proliferation by inducing apoptosis and repressed invasion in the
ESCC cell lines.
Conclusions: miR-302b is a potential molecular marker of ESCC and functions as a tumor suppressor by
post-transcriptionally regulating ErbB4.
Keywords: miR-302b, ErbB4, Esophageal squamous cell carcinomaIntroduction
Esophageal squamous cell carcinoma (ESCC) is a highly
aggressive neoplasm with geographic characteristics
and poor prognosis. About one half of all ESCC cases
in the world occur in China [1]. Over the past decades,
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stated.field of molecular targeted therapies [2]. One of the
attractive targets in ESCC is the ErbB/HER subfamily,
which regulates cellular proliferation, differentiation, and
programmed cell death [3]. The ErbB/HER subfamily of
receptor tyrosine kinases includes four members: EGFR
(also known as ErbB1 or HER1), ErbB2 (c-Neu or HER2),
ErbB3 (HER3), and ErbB4 (HER4) [4].
A multitude of studies have characterized the expression
and significance of the HER family in ESCC [5-10]. EGFR
and ErbB2 have been shown to be overexpressed in ESCCs
compared to non-tumor tissues, and these proteins are
important markers for the analysis of the prognosis and
clinical course of the disease [5-8]. ErbB3 is also up-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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to chemotherapy, but it has a limited prognostic value for
survival in ESCC [9,10]. ErbB4 is frequently up-regulated
in various cancer tissues [11-15], and experimental down-
regulation of ErbB4 in different tumor cells suppresses
growth [16-20]. Xu et al. found that extranuclear ErbB4
had negative effects on the progression of ESCC, whereas
the nuclear translocation of ErbB4 exhibited a tumor-
promoting property [12]. Pang et al. reported that
knockdown of ErbB4 inhibited migration and invasion
of the ESCC cell line Eca-109 [16]. However, to our
knowledge, the regulatory mechanism of ErbB4 in
ESCC is largely unknown.
MicroRNAs (miRNAs) represent a class of small non-
coding RNAs that regulate gene expression at the post-
transcriptional level. Currently, emerging results have
revealed that miRNAs are involved in cancer pathogenesis
and can function as oncogenes or tumor suppressor genes
[21]. miR-302b is a member of the miR-302 cluster, which
regulates the regulatory circuitry controlling ES cell
“stemness” [22]. Recently, it was found that the over-
expression of miR-302b induced caspase-3-mediated
apoptosis of the human neuroblastoma SH-SY5Y cell
line [23].
Since miRNAs predicted to target a gene can be searched
by online computational algorithm such as TargetScan
(http://www.targetscan.org/vert_50/) or PicTar (http://
pictar.mdc-berlin.de/). TargetScan and PicTar both pre-
dicted that ErbB4 is a target gene for miR-302b. Based
on these observations, the aim of this study was to
detect the expression of miR-302b in ESCC tissues
and analyze its correlation with clinicopathological
factors or prognosis, as well as to determine the post-
transcriptional regulatory relationship between miR-302b
and ErbB4. Furthermore, we examined whether ma-
nipulating the expression of miR-302b affected ESCC cell
behaviors, which could provide a potential molecular
therapeutic target for the treatment of human ESCC.
Methods
Patient samples and cell lines
Between January 2009 and December 2010, 60 patients
received resection for ESCC at First Affiliated Hospital,
Medical School, Xi’an JiaoTong University. Of these, the
tumor staging, clinicopathological information, or follow
up was incomplete for 10 patients. As a result, 50 patients
were retrospectively reviewed. None of these 50 patients
received neoadjuvant therapy before operation. Fresh
cancer tissues and paired normal adjacent tissues (NAT)
were obtained from these patients. The differentiation
grade, TNM stage, and lymph node status were classified
according to the UICC/AJCC TNM classification (seventh
edition). The Institutional Ethics Committee approved this
project and written informed consents were obtained fromthe patients. The ESCC cell lines (Eca109, Ec9706, and TE-
1) and esaphagel normal cell line (Het-1A) were obtained
from the Cell Bank of Shanghai (China) and cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS), 100 units/mL penicillin, and 100 g/mL
streptomycin at 37°C in a 5% CO2 incubator.
Quantitative reverse transcription-PCR (qRT-PCR) for
mature miRNA
qRT-PCR was carried out using the PrimeScript® RT
reagent Kit (Perfect Real Time) and a BioRad iQ5 Real-
Time PCR Detection System. The reverse transcription
reaction was carried out in a 20 μL volume with 1 μg
total RNA. The reaction was incubated at 37°C for
15 min, then 85°C for 5 sec; 1 μL of the RT product
was used in each PCR. The PCR cycling began with
template denaturation at 95°C for 5 min, followed by
40 cycles of 95°C for 10 sec, 60°C for 20 sec, and 72°C for
20 sec. U6 snRNA levels were used for normalization. The
following primer sequences were used in this section:
(1) ErbB4: random hexamers (RT primers), 5′-AGGAGTG
AAATTGGACACAGC-3′ (forward primer for qRT-PCR),
and 5′-TCCATCTCGGTATACAAACTGGT-3′ (reverse
primer for qRT-PCR); (2) miR-302b: 5′- GTCGTATCC
AGTGCGTGTCGTGGAGTCGGCAATTGCACTGGAT
ACGACCTACTAA -3′ (RT primer), 5′-GATAAGTGCT
TCCATGT-3′ (forward primer for qRT-PCR), and 5′-C
AGTGCGTGTCGTGGAGT- 3′ (reverse primer for qRT-
PCR); (3) U6: 5′-CGCTTCACGAATTTGCGTGTCAT-
3′ (RT primer), 5′-GCT TCGGCAGCACATATACTAAA
AT-3′ (forward primer for qRT-PCR), and 5′-CGCT TC
ACGAATTTGCGTGTCAT-3′ (reverse primer for qRT-
PCR). A control reaction without reverse transcriptase
was included, and the lack of signal from this reaction
ensured that there was no genomic DNA contamination.
In addition, the final PCR products were resolved using
agarose gel electrophoresis, and a single band of the
expected size indicated the specificity of the reaction.
The expression levels relative to U6 were calculated
using the formula 2-ΔΔCT.
Immunoblot analysis
For immunoblot analyses, 20 μg total proteins were
electrophoresed on a 10% SDS-PAGE gel, transferred to
PVDF membrane, blocked, and then incubated with
primary antibody. The blots were then incubated with the
corresponding horseradish peroxidase (HRP)-conjugated
secondary antibody at room temperature for 2 h. Then,
the membranes were visualized by exposure to X-ray
film in dark following a chemiluminescence reaction using
the enhanced ECL detection reagents (Amersham, Little
Chalfont, Buckinghamshire, England) according to the
manufacturer’s instructions. Densitometry analysis was
performed using the Scion Image software.
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The sequence of the precursor miR-302b was synthesized
and cloned into the pcDNA™6.2-GW/EmGFP-miR expres-
sion vector (Invitrogen, Carlsbad, CA, USA). The ErbB4
3′-UTR target site sequence and the sequence containing
the mutation of three bases in the miR-302b target site
were synthesized and cloned downstream of the lucifer-
ase gene in the pmirGLO luciferase vector (Promega,
Madison, WI, USA). All procedures were performed as
previously described [24]. These vectors were named
miR-302b, ErbB4-WT, and ErbB4-MT, respectively. All
constructs were sequenced. The anti-miR-302b inhibitor
(2′–O-methyl antisense oligonucleotide, anti-miR-302b)
and the anti-miR-inhibitors-Negative control (2′–O-
methyl scrambled miRNA, control) were purchased from
AngRang Inc. (Xi’an, China). Cell transfection was per-
formed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol. Total
RNA and protein were prepared 48 h after transfection
and were used for qRT-PCR or immunoblot analysis,
respectively. The DNA fragment sequences are listed
in Table 1.
Luciferase assay
The cells were co-transfected with ErbB4-WT or ErbB4-MT
and miR-302b or mock (pcDNA™6.2-GW/EmGFP-miR).
Luciferase activity was measured 24 h after transfection
using the Dual-Glo luciferase assay system (Promega,
Madison, WI, USA). All experimental protocols were per-
formed according to the manufacturer’s instructions. The
normalized firefly luciferase activity (firefly luciferase activ-
ity/Renilla luciferase activity) for each construct was com-
pared to that of the pmirGLO Vector no-insert control.
Cell viability assays
Cell viability was determined using an MTTassay according
to the manufacturer’s protocol. pcDNA™6.2-GW/EmGFP-
miR (mock) and anti-miR-inhibitors-Negative control
(control) were used as the controls for miR-302b and
anti-miR-302b, respectively. The absorbance of each
well was measured using a multidetection microplate
reader (BMG LABTECH, Durham, NC, USA) at a
wavelength of 570 nm. All experiments were performed







Erbb4-MT-antisense 5'-TCGAGAACAAATAAAATCell apoptosis assays
Cells were washed with PBS and resuspended in 500 μL
binding buffer containing 2.5 μL annexin V-phycoerythrin
(PE) and 5 μL 7-amino-actinomycin D (7-AAD) to deter-
mine the phosphatidylserine (PS) exposure on the outer
plasma membrane. After incubation, the samples were
analyzed using flow cytometry (FACSCalibur, BD Bio-
sciences, San Jose, CA). The experiment was repeated
three times.Cell invasion assay
Cell invasion was measured using transwell chambers
(Millipore, Billerica, USA) coated with Matrigel. After
transfection, the harvested cells were suspended in
serum free RPMI 1640 and were added into the upper
compartment of the chamber; conditioned RPMI 1640
medium with 20% (v/v) FBS was used as a chemo-
attractant and placed in the bottom compartment of
the chamber. After incubation, the cells were removed
from the upper surface of the filter with a cotton swab.
The invaded cells were then fixed and stained using
0.1% crystal violet. The cells were quantified from five
different fields under a light microscope. The experi-
ment was repeated in triplicate.Statistical analysis
To investigate the association of miR-302b expression
with clinicopathological features and survival, miR-302b
expression values were separated into low and high
expression groups using the median expression value
within the cohort as a cutoff. A Fisher’s exact text was
used to analyze the relationship between miR-302b and
the various clinicopathological characteristics. Progression-
free survival (PFS) was defined as the time from the first
day of treatment to the time of disease progression. The
survival curves were built according to the Kaplan-Meier
method, and the resulting curves were compared using the
log-rank test. The joint effect of covariables was examined
using the Cox proportional hazard regression model. For
other analyses, the data are expressed as the mean ± stand-
ard deviation. Differences between groups were assessed








Table 2 Clinicopathologic variables and the expression
status of miR-302b
Variables N miR-302b P
Low High
Age 0.168
<65 34 21 13
≥65 16 13 3
Gender 0.863
Male 29 20 9
Female 21 14 7
Smoking 0.301
Yes 37 27 11
No 13 7 6
Drink 0.137
Yes 30 18 12
No 20 16 4
Differentiation 0.010
Well + Moderate 39 23 16
Poor 11 11 0
TNM stage 0.230
I–II 19 11 8
III–IV 31 23 8
Lymph node status 0.001
Metastasis 30 26 4
No metastasis 20 8 12
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Expression of miR-302b in ESCC and its significance
We examined the expression of miR-302b in a set of 50
paired samples using qRT-PCR. The results showed that
miR-302b was significantly down-regulated in ESCC
tissues when compared to the NAT (20 ± 3.42 vs 40 ±
5.24, P < 0.05, Figure 1A). Next, the correlation of miR-
302b with the clinicopathological factors was examined.
There was a correlation between the miR-302b expression
status and the presence of lymph node metastases
(Table 2). A low level of miR-302b expression and
lymph nodes metastases correlated with a decreased
progression-free survival (PFS) according to the Kaplan-
Meier survival curve analysis with a log rank compari-
son; the other parameters were not significant (Table 3,
Figure 1B). Decreased expression of miR-302b was an
independent prognostic factor for PFS (Table 4).
ErbB4 is a target of miR-302b
We first determined the expression levels of ErbB4 protein
and miR-302b in three different esophageal cancer cell
lines (Eca109, Ec9706, and TE-1) and one esaphagel
normal cell line (Het-1A). We found that each cell line
expressed higher level of ErbB4 protein and lower level
of miR-302b than that in Het-1A (P < 0.05, Figure 2A,
B, and C). Further, TE-1 had the highest expression
levels of ErbB4 protein but lowest expression levels of
miR-302b, while Ec9706 had the highest expression
levels of ErbB4 protein but lowest expression levels
of miR-302b. Therefore, we analyzed the relationship
between the miR-302b expression level and ErbB4
protein expression level in the specimens of the patients.
The result demostrated that miR-302b negatively correlated
with the ErbB4 protein expression (Figure 2D, P < 0.05,
r = −0.725). Then, TE-1 and Ec9706 were chosen for
following experiments. After confirming that anti-miR-Figure 1 Expression of ErbB4 in esophageal squamous cell carcinoma
specimens of ESCC tissues and matched normal adjacent tissues (NAT) are
with high miR-302b expression had a longer progression-free survival com302b or miR-302b could significantly change the expres-
sion level of miR-302b using qRT-PCR, we then tested
the effect of miR-302b on the expression of ErbB4 mRNA
and protein. The results showed that miR-302b signifi-
cantly decreased the expression of ErbB4 protein (P < 0.05,
Figure 2E and F), but had no effect on mRNA expression. A) Relative expression of miR-302b expression levels in 50 surgical
shown. The data are presented as 2-ΔCT values (*P < 0.05). (B) Patients
pared to patients with low miR-302b expression.
Table 3 Univariate analysis for progression free survival
Variables N Progression free survival (months) P
Median ± SE 95% CI
miR-302b 0.001
Low 34 12.92 ± 1.03 10.91-14.93
High 16 19.82 ± 0.77 18.32-21.33
Age 0.676
<65 34 17.29 ± 1.23 15.28-19.31
≥65 16 17.20 ± 2.63 12.05-22.35
Gender 0.586
Male 29 17.26 ± 1.08 15.12-19.36
Female 21 18.63 ± 1.45 15.78-21.47
Smoking 0.173
Yes 37 16.37 ± 0.95 14.50-18.24
No 13 18.94 ± 1.72 15.56-22.31
Drinking 0.365
Yes 30 16.89 ± 1.15 14.63-19.15
No 20 18.09 ± 1.17 15.80-20.39
Differentiation 0.108
Well + Moderate 39 17.87 ± 1.00 15.91-19.83
Poor 11 14.00 ± 2.54 9.20-18.80
TNM stage 0.716
I–II 19 18.04 ± 1.22 15.65-20.43
III–IV 31 16.79 ± 1.39 14.07-19.51
Lymph node 0.005
Metastasis 30 14.67 ± 1.35 12.03-17.31
No metastasis 20 20.2 ± 0.84 18.56-21.85
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the 3′-UTR of ErbB4 was a functional target of miR-
302b in TE-1 cells. After co-transfection of miR-302b
with either the ErbB4-wild type or mutated 3′-UTR
luciferase reporter vector into TE-1 cells, we found that
miR-302b reduced the activity of the luciferase reporterTable 4 Multivariate Cox proportional hazards analysis
for progression free survival
Variables Progression free survival P
HR 95% CI
miR-302b
Low vs high 5.86 1.73-19.84 0.005
Lymph node
Metastasis vs no metastasis 1.82 0.67-4.87 0.238
TNM stage
III–IV vs I–II 1.25 0.57-2.72 0.583
Differentiation
Well + moderate vs poor 0.89 0.31-2.54 0.826fused to the wild-type ErbB4 3′-UTR by 60%. However,
mutation of the 3-nt sequence in the ErbB4 3′-UTR com-
plementary to the miR-302b seed sequence restored the
luciferase activity of the miR-302b transfected cells from
60% to 90%, showing that the action of miR-302b on
ErbB4 depended on the presence of a single miR-302b
cognate binding site within the 3′-UTR (Figure 2H and I).
miR-302b represses cell proliferation by inducing apoptosis
To investigate whether miR-302b modulates cell prolif-
eration in esophageal cancer cells, we assayed its effect
on cell proliferation activity. The proliferation activity
of TE-1 and Ec9706 cells transfected with anti-miR-
302b or miR-302b was determined using an MTT assay.
As shown in Figure 3A and B, cells treated with anti-
miR-302b had a significant increase in cell viability
when compared with the anti-miR-NC transfected cells
(P < 0.05). In contrast, overexpression of miR-302b re-
sulted in a decrease in absorbance (P < 0.05). Further
experiments demonstrated that this cell proliferation
inhibition effect was partly due to the induction of
apoptosis (Figure 3C,D and E). These results indicated
that ESCC cell growth can be modulated through miR-
302b-mediated ErbB4 repression.
miR-302b regulates cell invasion in vitro
Because there was a correlation between miR-302b and
lymph node metastasis, a transwell assay was performed
to investigate the role of miR-302b on the invasion of
ESCC cells. Overexpression of miR-302b repressed the
cell invasion ability of TE-1 cells, while down-regulation
of miR-302b expression had contrary results (P < 0.05,
Figure 4A and B). The same result was also confirmed in
Ec9706 cells. These findings suggest that miR-302b regu-
lates cell invasion of the ESCC cell lines in vitro.
Discussion
ErbB4 expression has been noted in various tumors, such
as esophagus, colon, prostate, ovary, lung, breast, and
thyroid [12-15,25-27]. Moreover, recent findings about
somatic mutations that activate ErbB4 in metastatic
melanoma have started to support a casual role of ErbB4
in carcinogenesis and to support the development of tools
[28], such as ErbB4 antibodies, to target ErbB4 in cancer
[29]. However, reports about the role of ErbB4 in ESCC
are limited.
Previous studies have reported that miRNAs play im-
portant roles in gene expression regulation. However, the
expression and the regulatory mechanisms of the ErbB4
gene in ESCC have not been reported. Using bioinformat-
ics, ErbB4 was found to be a predicted target of miR-302b.
miR-302b is a member of the miR-302 cluster, which is
specifically expressed in pluripotent human embryonic
stem cells but not in differentiated embryoid bodies or
Figure 2 miR-302b post-transcriptionally regulates ErbB4 expression. (A-B) The expression of ErbB4 protein in ESCC cell lines (Eca109, Ec9706,
and TE-1) and esaphagel normal cell line (Het-1A) were analyzed using immunoblot analysis. (C) The expression of miR-302b in three esophageal
cancer cell lines and Het-1A were analyzed using RT-PCR. (D) The relationship between the miR-302b expression level and ErbB4 protein expression
level in the specimens of the patients were analyzed. (E-F) The effect of miR-302b on ErbB4 protein expression was detected using immunoblot analysis
in TE-1 cells. (G) The effect of miR-302b on the mRNA expression of ErbB4 was detected using qRT-PCR in TE-1 cells. (H) Luciferase reporter assay in TE-1
cells. (I) Diagram of the ErbB4 3'-UTR containing reporter constructs. “miR-302b” represents cells transfected with pcDNA™6.2-GW/EmGFP-miR-302b;
“control” represents normal ESCC cells; “mock” represents cells transfected with pcDNA™6.2-GW/EmGFP-miR; “ErbB4-MT” and “ErbB4-WT” represent the
mutated and wild type luciferase vectors, respectively. *P < 0.05 compared to control or mock respectively.
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reprogram human skin cancer cells into a pluripotent
ES cell-like state [22]. It was found that overexpression
of miR-302b induced caspase-3-mediated apoptosis in
the human neuroblastoma SH-SY5Y cell line [23]. But,a recent report found that miR-302b is overexpressed
in primary human tumors specimens, and the down-
regulation of miR-302b effectively decreased tumor cell
growth in human head and neck squamous cell carcin-
oma patients [31].
Figure 3 Effect of miR-302b on cell proliferation and apoptosis. (A-B) After pcDNA™6.2-GW/EmGFP-miR-302b (miR-302b) or Anti-miR-302b
inhibitor (anti-miR-302b) transduction, the growth of TE-1 cells (A) and Ec9706 cells (B) was analyzed at different time points and compared to
anti-miR-Inhibitors-Negative Control (control)/pcDNA™6.2-GW/EmGFP-miR (mock) cells using the MTT assay. (C) Flow cytometric analysis of the ef-
fect of miR-302b on apoptosis of TE-1 cells. (D-E) Flow cytometric analysis of the effect of miR-302b on the apoptosis of TE-1 cells (D) and
Ec9706 cells (E). *P < 0.05 compared with the respective control.
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Figure 4 Effect of miR-302b on cell invasion in vitro. (A-B) Cells transfected with the anti-miR-302b inhibitor (anti-miR-302b), anti-miR-
Inhibitors-Negative Control (control), pcDNA™6.2-GW/EmGFP-miR-302b (miR-302b), or pcDNA™6.2-GW/EmGFP-miR (mock) were subjected to
transwell invasion assays. (C-D) The invasive cell numbers are the average count of five random microscopic fields detected using the transwell
invasion assay. A and C: TE-1 cells; B and D: Ec9706 cells. Each bar represents the mean ± SD of the counts. *P < 0.05 compared with the
respective control.
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in tumor tissues compared to paired normal adjacent
tissues. There were significant correlations between the
expression of miR-302b and lymph node metastasis and
differentiation. Furthermore, a low expression level of
miR-302b was an independent factor that indicated poor
prognosis in ESCC patients. This evidence suggests that
down-regulation of miR-302b in tumor cells may play
roles in the development of ESCC and may have prog-
nostic value.We then investigated whether ErbB4 could be regu-
lated by miR-302b and the effect that miR-302b had on
ESCC cell behaviors. Our study documented that ErbB4
protein expression was negatively regulated by miR-302b
both in cell and tissue analysis. The overexpression of
miR-302b significantly decreased the ErbB4 protein
level but not mRNA level in ESCC cells, indicating the
post-transcriptional down-regulation of ErbB4 by miR-
302b. Moreover, the overexpression of miR-302b sig-
nificantly decreased the luciferase activity of pmirGLO
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did not decrease the activity of pmirGLO that con-
tained the ErbB4 3′-UTR mutant sequence, indicating
that the target site was specific. Furthermore, to reveal
the exact role of miR-302b in ESCC, we tested the
effect of miR-302b on proliferation, apoptosis, and in-
vasion by up- and down-regulating the expression level
of miR-302b. The results suggested that miR-302b
acted as a tumor suppressor gene in ESCC by inhibiting
proliferation, inducing apoptosis, and repressing invasion.
Contrary to our observations, Murray et al. showed
that miR-302b was overexpressed in malignant germ
cell tumors compared to normal gonad and benign
germ cell tumors [32]. But miR-302b function as a
tumor suppressor gene both in gastric cancer by targeting
EGFR [33]. These results indicate that onco-miRNAs
and suppressor-miRNAs can regulate two different
roles of the same gene, behaving as oncogenes or
tumor suppressors, depending on the tissue type and
specific targets [34]. We will carry out further in vivo
experiments to confirm the role of miR-302b and its
target genes in ESCC.
Conclusions
This was the first study to evaluate the relationship
between ErbB4 and miR-302b in ESCC. Our findings
demonstrated that ErbB4 was up-regulated in ESCC,
and expression of ErbB4 was correlated with tumor
differentiation and lymph node metastasis. We found
that miR-302b post-transcriptionally down-regulated ErbB4
expression in vitro. We also concluded that miR-302b
inhibited proliferation by inducing apoptosis and repressed
the invasive ability of ESCC cells, and an ErbB4-mediated
pathway may be involved in this function.
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